CJC-1295 + Ipamorelin: The GH Secretagogue Stack, Read Carefully
CJC-1295 and ipamorelin are the most commonly paired growth-hormone secretagogues in the research-peptide conversation. They are not growth hormone — they are signals that push the body's own pituitary pulses. The mechanism is interesting; the human evidence is thinner than the online discussion suggests.
CJC-1295 acts on the GHRH receptor; ipamorelin acts on the GHSR (ghrelin) receptor — complementary pathways.
endogenous GH release is pulsatile; secretagogues amplify pulses rather than producing flat elevations.
both are prohibited under WADA's peptide hormones / growth factors category, in and out of competition.
neither is approved for any human indication in major jurisdictions.
CJC-1295 is a long-acting GHRH analogue. Ipamorelin is a selective ghrelin-receptor agonist (GHRP) with low prolactin and cortisol effects compared to older GHRPs. Combined, they engage both arms of pituitary GH regulation simultaneously, producing larger GH pulses than either alone in animal and limited human pharmacological studies. Long-term efficacy and safety data in humans are limited; both molecules sit in a regulatory and sport-ban grey zone.
Pushing pituitary pulses is not the same as injecting exogenous GH. The pharmacology is more elegant, the human evidence base is much thinner.
What they are
CJC-1295 is a synthetic analogue of GHRH (growth-hormone-releasing hormone). The 'DAC' version (with a drug affinity complex) binds albumin and extends half-life from minutes to roughly a week. The 'no-DAC' version (also called Mod GRF 1-29) is short-acting.
Ipamorelin is a synthetic pentapeptide ghrelin-receptor agonist — a 'GHRP' (growth hormone-releasing peptide) — selected during development for selective GH release with minimal prolactin or cortisol increase compared to earlier GHRPs like GHRP-2 or GHRP-6.
The pairing rationale: GHRH analogues and GHRPs act on different receptors that converge on GH release. Combined administration produces additive or synergistic GH pulses in published pharmacological studies.
How the two molecules complement
| Layer | What the research describes |
|---|---|
| Receptor target | CJC-1295: GHRH receptor (somatotrope membrane). Ipamorelin: GHSR (ghrelin receptor). |
| GH release mechanism | GHRH increases somatotrope cAMP; GHRP suppresses somatostatin tone and amplifies GHRH response. |
| Pulse shape | Combined administration produces larger GH pulses; pulsatility is preserved more than with exogenous GH. |
| Selectivity | Ipamorelin selected for minimal prolactin/cortisol stimulation vs older GHRPs. |
| Half-life | CJC-1295 DAC ~6–8 days; ipamorelin ~2 hours. |
The architecture is elegant: two complementary signals pushing the same end-organ. The clinical relevance of preserved pulsatility vs flat GH replacement is debated.
What the human evidence actually shows
Pharmacological GH response
Published studies confirm GH and IGF-1 rises after CJC-1295 administration; pulsatile patterns documented.
Body composition
Limited published human data on body-composition outcomes from CJC-1295/ipamorelin protocols specifically; most claims extrapolate from GH or other secretagogues.
Clinical use
Neither molecule is approved for any human indication. Some compounded use in age-management contexts exists in some jurisdictions but is not standard medicine.
The honest framing is: pharmacological GH-release data are clear; downstream clinical outcomes (composition, strength, recovery) in humans are not established at the trial level. Animal data and mechanistic plausibility exist; large blinded human RCTs do not.
Both molecules also carry regulatory complexity. They are not approved medicines and are prohibited in tested sport under WADA's S2 category. The research-compound grey zone they occupy is real but not a substitute for clinical evidence.
What we know, what's still open
- GH/IGF-1 elevation: Documented in pharmacological studies.
- Pulsatile preservation: Mechanistic data; clinical relevance debated.
- Body composition outcomes: Thin human evidence specific to this stack.
- Long-term safety: Not established at trial scale.
- Sport / regulatory status: Both prohibited under WADA S2; not approved by EMA, MHRA or FDA.
Frequently asked
Is this safer than HGH because it's the body's own GH?
Mechanistically interesting argument, clinically unproven. 'Endogenous' release does not equal 'safer outcomes' without trial data.
Why pair them?
GHRH analogues and GHRPs act on different receptors that converge on GH release; combined administration produces larger GH pulses in published studies.
Are these legal in the EU?
Not approved medicines, sit in research-compound grey zone, prohibited in tested sport. See our EU peptide legality reference.
What about side effects?
GH-mediated effects (water retention, glucose handling shifts, possible insulin resistance) are plausible. Long-term safety in humans not characterised.
Where to read further
- • Sackmann-Sala L et al. CJC-1295 pharmacology and GH response.
- • Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998.
- • Sigalos JT, Pastuszak AW. The safety and efficacy of GH secretagogues. Sex Med Rev 2018.